• Dosage of Eritroderm in details
• Eritroderm interactions
• Eritroderm reviews

Dosage of Eritroderm in details

Eritroderm Dosage

Generic name: Eritroderm STEARATE 250mg

Dosage form: tablet, film coated

See also:

• Eritroderm Injection USP injection, powder, lyophilized, for solution

The information at Drugs.com is not a substitute for medical advice. Always consult your doctor or pharmacist.

In most patients, Eritroderm® STEARATE Film-coated tablets are well absorbed and may be dosed orally without regard to meals. However, optimal blood levels are obtained when Eritroderm® STEARATE tablets are given in the fasting state (at least 1/2 hour and preferably 2 hours before meals).

Adults

The usual dosage is 250 mg every 6 hours; or 500 mg every 12 hours. Dosage may be increased up to 4 g per day according to the severity of the infection. However, twice-a-day dosing is not recommended when doses larger than 1 g daily are administered.

Children

Age, weight, and severity of the infection are important factors in determining the proper dosage. The usual dosage is 30 to 50 mg/kg/day, in equally divided doses. For more severe infections this dosage may be doubled but should not exceed 4 g per day.

In the treatment of streptococcal infections of the upper respiratory tract (e.g., tonsillitis or pharyngitis), the therapeutic dosage of Eritroderm should be administered for at least ten days.

The American Heart Association suggests a dosage of 250 mg of Eritroderm orally, twice a day in long-term prophylaxis of streptococcal upper respiratory tract infections for the prevention of recurring attacks of rheumatic fever in patients allergic to penicillin and sulfonamides.4

Conjunctivitis of the Newborn Caused by Chlamydia trachomatis

Oral Eritroderm suspension 50 mg/kg/day in 4 divided doses for at least 2 weeks.4

Pneumonia of Infancy Caused by Chlamydia trachomatis

Although the optimal duration of therapy has not been established, the recommended therapy is oral Eritroderm suspension 50 mg/kg/day in 4 divided doses for at least 3 weeks.

Urogenital Infections During Pregnancy Due to Chlamydia trachomatis

Although the optimal dose and duration of therapy have not been established, the suggested treatment is 500 mg of Eritroderm by mouth four times a day or two Eritroderm 333 mg tablets orally every 8 hours on an empty stomach for at least 7 days. For women who cannot tolerate this regimen, a decreased dose of one Eritroderm 500 mg tablet orally every 12 hours, one 333 mg tablet orally every 8 hours or 250 mg by mouth four times a day should be used for at least 14 days.6

For adults with uncomplicated urethral, endocervical, or rectal infections caused by Chlamydia trachomatis when tetracycline is contraindicated or not tolerated

500 mg of Eritroderm by mouth four times a day or two 333 mg tablets orally every 8 hours for at least 7 days.6

For patients with nongonococcal urethritis caused by Ureaplasma urealyticum when tetracycline is contraindicated or not tolerated

500 mg of Eritroderm by mouth four times a day or two 333 mg tablets orally every 8 hours for at least seven days.6

Primary Syphilis

30 to 40 g given in divided doses over a period of 10 to 15 days.

Acute Pelvic Inflammatory Disease Caused by N. gonorrhoeae

500 mg Eritroderm Lactobionate-I.V. (Eritroderm lactobionate for injection, USP) every 6 hours for 3 days, followed by 500 mg of Eritroderm base orally every 12 hours, or 333 mg of Eritroderm base orally every 8 hours for 7 days.

Intestinal Amebiasis

Adults

500 mg every 12 hours, 333 mg every 8 hours or 250 mg every 6 hours for 10 to 14 days.

Children

30 to 50 mg/kg/day in divided doses for 10 to 14 days.

Pertussis

Although optimal dosage and duration have not been established, doses of Eritroderm utilized in reported clinical studies were 40 to 50 mg/kg/day, given in divided doses for 5 to 14 days.

Legionnaires' Disease

Although optimal dosage has not been established, doses utilized in reported clinical data were 1 to 4 g daily in divided doses.

More about Eritroderm (Eritroderm)

• Side Effects
• During Pregnancy or Breastfeeding
• Dosage Information
• Drug Interactions
• Support Group
• 2 Reviews - Add your own review/rating

Consumer resources

• Eritroderm
• Eritroderm

  Oral (Advanced Reading)

• Other brands: Eritroderm, EryPed, Eryc, Ilosone, More (4) »

Professional resources

• Eritroderm (FDA)
• More (2) »

Other formulations

• Eritroderm Stearate Filmtab
• Eritroderm Lactobionate

Related treatment guides

• Bacterial Endocarditis Prevention
• Bartonellosis
• Bowel Preparation
• Bronchitis
• Bullous Pemphigoid
• More (20) »

What other drugs will affect Eritroderm?

Many drugs can interact with Eritroderm. Not all possible interactions are listed here. Tell your doctor about all your medications and any you start or stop using during treatment with Eritroderm, especially:

• antiviral medicine (drugs to treat hepatitis, or HIV/AIDS);

• antifungal medicine;

• any other antibiotic medicines;

• cancer medicine;

• drugs that lower cholesterol or triglycerides;

• drugs to treat or prevent malaria;

• drugs to treat pulmonary arterial hypertension;

• heart or blood pressure medication;

• medicine to prevent organ transplant rejection; or

• medicine to treat depression or mental illness.

This list is not complete and many other drugs can interact with Eritroderm. This includes prescription and over-the-counter medicines, vitamins, and herbal products. Give a list of all your medicines to any healthcare provider who treats you.

Eritroderm interactions

Eritroderm use in patients who are receiving high doses of theophylline may be associated with an increase in serum theophylline levels (Eritroderm ethylsuccinate) and potential theophylline toxicity. In case of theophylline toxicity and/or elevated serum theophylline levels, (Eritroderm ethylsuccinate) the dose of theophylline should be reduced while the patient is receiving concomitant Eritroderm therapy.

Hypotension, bradyarrhythmias, and lactic acidosis have been observed in patients receiving concurrent verapamil, belonging to the calcium channel blockers drug class.

Concomitant administration of Eritroderm and digoxin has been reported to result in elevated digoxin serum levels. (Eritroderm ethylsuccinate)

There have been reports of increased anticoagulant effects when Eritroderm and oral anticoagulants were used concomitantly. Increased anticoagulation effects due to interactions of Eritroderm with various oral anticoagulants may be more pronounced in the elderly.

Eritroderm is a substrate and inhibitor of the 3A isoform subfamily of the cytochrome p450 enzyme system (CYP3A). Coadministration of Eritroderm and a drug primarily metabolized tions. Interactions with other drugs metabolized by the CYP3A isoform are also possible. The following CYP3A based drug interactions have been observed with Eritroderm products in post-marketing experience:

Ergotamine/dihydroergotamine

Concurrent use of Eritroderm and ergotamine or dihydroergotamine has been associated in some patients with acute ergot toxicity characterized by severe peripheral vasospasm and dysesthesia.

Triazolobenzodiazepines (such as triazolam and alprazolam) and related benzodiazepines

Eritroderm has been reported to decrease the clearance of triazolam and midazolam, and thus, may increase the pharmacologic effect of these benzodiazepines.

HMG-CoA Reductase Inhibitors

Eritroderm has been reported to increase concentrations of HMG-CoA reductase inhibitors (e.g., lovastatin and simvastatin). Rare reports of rhabdomyolysis have been reported in patients taking these drugs concomitantly.

Sildenafil (Viagra)

Eritroderm has been reported to increase the systemic exposure (AUC) of sildenafil. Reduction of sildenafil dosage should be considered.

There have been spontaneous or published reports of CYP3A based interactions of Eritroderm with cyclosporine, carbamazepine, tacrolimus, alfentanil, disopyramide, rifabutin, quinidine, methylprednisolone, cilostazol, vinblastine, and bromocriptine.

Concomitant administration of Eritroderm with cisapride, pimozide, astemizole, or terfenadine is contraindicated.

In addition, there have been reports of interactions of Eritroderm with drugs not thought to be metabolized by CYP3A, including hexobarbital, phenytoin, and valproate.

Eritroderm has been reported to significantly alter the metabolism of the nonsedating antihistamines terfenadine and astemizole when taken concomitantly. Rare cases of serious cardiovascular adverse events, including electrocardiographic QT/QT interval prolongation, cardiac arrest, torsades de pointes, and other ventricular arrhythmias have been observed. In addition, deaths have been reported rarely with concomitant administration of terfenadine and Eritroderm.

There have been post-marketing reports of drug interactions when Eritroderm is co-administered with cisapride, resulting in QT prolongation, cardiac arrhythmias, ventricular tachycardia, ventricular fibrillation, and torsades de pointes, most likely due to inhibition of hepatic metabolism of cisapride by Eritroderm. Fatalities have been reported.

Drug/Laboratory Test Interactions

Eritroderm interferes with the fluorometric determination of urinary catecholamines.

References

1. DailyMed. "ERYTHROMYCIN: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
2. FDA/SPL Indexing Data. "63937KV33D: The UNique Ingredient Identifier (UNII) is an alphanumeric substance identifier from the joint FDA/USP Substance Registration System (SRS).". https://www.fda.gov/ForIndustry/Data... (accessed September 17, 2018).
3. MeSH. "Protein Synthesis Inhibitors". https://www.ncbi.nlm.nih.gov/mesh/68... (accessed September 17, 2018).

Reviews

User reports

Consumer reviews

Information checked by Dr. Sachin Kumar, MD Pharmacology